prices
23.03.2017
Cassation Court pronounced legitimacy of FAS refusal to increase threefold prices for “Prostenongel” medicinal drugmore![Cassation Court pronounced legitimacy of FAS refusal to increase threefold prices for “Prostenongel” medicinal drug](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/Эмилю_.jpg)
Earlier Courts of two instances confirmed legitimacy of the efforts of the antimonopoly body and the rightness of applying the established requirements to register prices for vital and essential drugs
more
![FAS made a decision: a Russian subsidiary of “Apple” coordinated iPhone prices](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/lori-0021700481-bigwww.jpg)
On 14 March, FAS found that “Apple Rus” Ltd. had coordinated economic activity of Apple iPhone Smartphone resellers that resulted in fixing and marinating prices for them (in breach of Part 5 Article 11 of the Federal Law “On Protection of Competition”)
more
![FAS achieved reduction of prices for 207 medicinal drugs](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/Биокад снизил цены на лекарства - ФАС России.jpg)
Pharmaceutical companies continue reducing drug prices upon the findings of an international comparative survey carried out by FAS
more
![FAS abolished agreed prices for “Bartizar” medicinal drug](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/lori-0005868896-bigwww_slider.jpg)
The FAS Russia established that the drug manufacturer submitted false information on the prices of raw materials supplies and set an excessive euro exchange rate in its estimates
more
![FAS position on compiling the list of vital and essential drugs](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/blister.jpg)
The FAS Russia considered a petition of “Johnson & Johnson” Ltd. on the need to re-file a proposal to include medicinal drugs in the list of vital and essential drugs for 2018
more